GRI Bio (GRI) Stock News, May-Jul 2025

GRI Bio (NASDAQ: GRI) has reported encouraging 6-week interim biomarker data from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The study, which has completed enrollment of approximately 35 subjects, showed that GRI-0621 treated patients demonstrated favorable reduction in fibrogenesis biomarkers and increased basement membrane remodeling.

The Independent Data Monitoring Committee (IDMC) has recommended continuing the study as planned, noting no safety concerns in the data reviewed. The trial remains blinded, with patients randomized in a 2:1 ratio for GRI-0621 4.5mg or placebo. The company expects to report topline results in Q3 2025, with additional pulmonary function test data expected in the coming weeks.

GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.

During the conference, CEO Marc Hertz, PhD shared insights about his leadership journey, his commitment to the company, and his enthusiasm for GRI Bio's development programs. The presentation is now available for viewing on virtualinvestorco.com and the company's investor relations website.

GRI Bio (NASDAQ: GRI) has completed patient enrollment in its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The study enrolled approximately 35 subjects randomized in a 2:1 ratio to receive either GRI-0621 4.5mg or placebo once daily for 12 weeks.

The company reported positive interim safety results, with GRI-0621 demonstrating safety and tolerability in both 2-week (12 patients) and 6-week (24 patients) analyses. Notably, no hyperlipidemia was observed in treated patients, and interim biomarker results from the first 12 subjects at 2 weeks suggested potential anti-fibrotic effects.

The study's primary endpoint focuses on safety and tolerability after 12 weeks of treatment, with secondary endpoints including changes in serum biomarkers, pharmacokinetics, and pharmacodynamic activity. The company expects to report 6-week interim biomarker data in July 2025 and topline results in Q3 2025.

GRI Bio (NASDAQ: GRI) has reported positive interim safety results from its Phase 2a study of GRI-0621, a RAR-βɣ dual agonist for treating Idiopathic Pulmonary Fibrosis (IPF). The Independent Data Monitoring Committee (IDMC) found no safety concerns in the first 24 patients after 6 weeks of treatment and recommended continuing the study.

The trial involves approximately 36 subjects randomized in a 2:1 ratio, receiving either 4.5mg GRI-0621 or placebo daily for 12 weeks. The drug demonstrated favorable safety profiles with no adverse events related to hyperlipidemia. The company expects to report 6-week interim biomarker data in July 2025 and topline results in Q3 2025.

GRI Bio (NASDAQ: GRI) presented positive preclinical data for GRI-0621, their lead program targeting pulmonary fibrosis, at the 2025 ATS International Conference. The data shows GRI-0621, a small molecule RAR-βɣ dual agonist, effectively resolves inflammation and fibrosis in bleomycin-induced fibrosis models. Key findings demonstrate that GRI-0621 significantly inhibits lung injury and fibrotic drivers, performing as well or better than approved drug nintedanib. In the ongoing Phase 2a clinical trial, interim analysis of the first 12 patients showed GRI-0621 to be safe and well-tolerated, with no hyperlipidemia observed. The interim biomarker results suggest anti-fibrotic effects based on PRO-C3 changes. The company expects topline results from the Phase 2a study in Q3 2025.

GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor Closing Bell Series. CEO Marc Hertz, PhD will present on May 28, 2025, at 4:00 PM ET.

The event will include a corporate overview, business outlook, and a live Q&A session with investors. The presentation will be webcast live on the company's website and will remain accessible for 90 days after the event.

GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in A.G.P.'s Annual Healthcare Company Showcase. CEO Marc Hertz, PhD will engage in a fireside chat on Wednesday, May 21, 2025, at 2:40 PM ET. The virtual event will be accessible via webcast through the Events page in the Investors section of GRI Bio's website.

GRI Bio (NASDAQ: GRI) reported its Q1 2025 financial results and provided updates on its Phase 2a trial of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF). The company highlighted positive interim 2-week safety and biomarker results from the first 12 patients, showing an anti-fibrotic effect trend. Patient enrollment for the 6-week interim analysis (n=24) is complete, with over two-thirds of overall trial enrollment finished. The company recently closed a $5.0 million public offering and reported a Q1 2025 net loss of $3.0 million. With current cash of $3.3 million plus the new offering, GRI Bio expects to fund operations through Q3 2025. Key upcoming milestones include 6-week interim results in Q2 2025 and topline results in Q3 2025.

GRI Bio (NASDAQ: GRI) reported encouraging interim biomarker results from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF). The Independent Data Monitoring Committee (IDMC) found that the first 12 patients showed a positive trend towards anti-fibrotic effects, with no safety concerns. The company has completed enrollment for the 6-week interim analysis (N=24) and achieved over 70% total enrollment. The Phase 2a study is a randomized, double-blind trial evaluating GRI-0621 4.5mg versus placebo in approximately 36 IPF patients. Key timelines include interim data expected in Q2 2025 and topline results in Q3 2025. Initial 2-week safety results showed GRI-0621 to be well-tolerated, with no hyperlipidemia observed and lipid levels remaining within normal ranges.